#United States #Class Action #San Jose #Twist Bioscience #Security Settlement

Proposed Settlement for Twist Bioscience Securities Litigation

A proposed settlement has been reached in the class action case involving Twist Bioscience Corporation, following claims regarding securities misrepresentations. This important legal proceeding, identified as Anthony Joseph Peters v. Twist Bioscience Corporation, encompasses actions taken between December 20, 2018, and November 15, 2022. The settlement, valued at $17,050,000, aims to resolve claims made by individuals who acquired the company's common stock during this designated period. This brief will shed light on key aspects of the case and what impacted parties should consider moving forward.

Settlement Details

For all individuals or entities who purchased Twist common stock either during the December 2020 offering or within the specified timeline, a court hearing is set for November 18, 2026. The court, located in San Jose, California, under the direction of Judge Eumi K. Lee, will determine whether the proposed settlement should be approved as fair and sufficient. Additionally, the court will discuss the certification of a Settlement Class, which includes all affected shareholders, while not excluding any individuals or entities outlined in the detailed Long-Form Notice.

Understanding the Implications

The proposed resolution signifies an essential step toward compensating affected stakeholders, given that they will be able to submit claims for a share in the Net Settlement Fund. Members of the Settlement Class are encouraged to complete and submit a Proof of Claim and Release form before the November 17, 2026 deadline. Failing to submit this claim may lead to disqualification from receiving any portion of the settlement.

By accepting the proposed settlement terms, shareholders will effectively relinquish their rights to pursue any claims related to the litigation. This has been a prominent part of the settlement discussions, as it establishes a framework for protecting both the company and its investors from further disputes regarding the issues raised in the lawsuit.

Exclusion and Objection Process

Those who wish to dissociate themselves from the Settlement Class have until October 7, 2026 to submit requests for exclusion. Those remaining within the class will proceed through the planned processes without the option to assert further claims related to the case. Concurrently, any objections regarding the settlement terms or the proposed Plan of Allocation need to be submitted to the court by the same exclusion deadline.

Final Considerations

This class action lawsuit illustrates the complexities associated with securities transactions and the responsibilities of public companies to provide transparent information to their shareholders. The upcoming court hearing will be an essential opportunity for stakeholders to gain clarity on the outcome of their involvement with Twist Bioscience.

For more detailed information, affected parties can visit TwistSecuritiesSettlement.com. It is recommended that shareholders stay informed about their rights and the forthcoming legal proceedings.

As the date approaches, interested parties are reminded to consider their options judiciously, as this proposed settlement shapes not only the future of Twist Bioscience but also sets a precedent within the realm of securities litigation. The outcome aims to bring closure and, ideally, restitution for those impacted by the litigation's claims, marking a significant chapter in the company's corporate governance practices.